The best example for molecular targeted therapy in mesenchymal tumors is treatment with tyrosine kinase inhibitors in gastrointestinal stromal tumors (GIST) which carry activating KIT or PDGFRA (platelet derived growth factor receptor alpha) mutations in approximately 90%. Here, PDGFRA is linked to gastrointestinal stromal tumor.